Posted by Michael Wonder on 03 Aug 2016
CADTH calls for patient input on a submission from Horizon Pharmaceuticals for Ravicti (glycerol phenylbutyrate)
2 August 2016 - CADTH has called for patient input from Horizon Pharmaceuticals for Ravicti.
Health Canada approved Ravicti (glycerol phenylbutyrate) on 18 March 2016 for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
The submission is due on 29 August 2016.
